Checking if a PET scan can predict the dose of lutetium therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial is testing whether a special PET scan before treatment can predict what dose of a radioactive drug will go to your cancer, helping doctors plan and personalize your care. The drug used is called 177Lu-PSMA-617, which targets prostate cancer cells that have a specific marker (PSMA).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have prostate cancer that has spread and no longer responds to hormone therapy.
- You must have already had chemotherapy with a taxane drug and at least one newer hormone therapy.
- You must be able to lie still for about 1 hour and 20 minutes to have the imaging tests.
- You must not have any allergies to the study drugs or have a pacemaker or defibrillator that prevents imaging.
- You must not have urinary tract blockage, a urinary catheter, or incontinence that interferes with exams.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This trial will test if a special PET scan (18F-DCFPyL) can help doctors plan your treatment with a radioactive medicine called 177Lu-vipivotide tetraxetan. You are eligible if you already qualify for that standard therapy and have had a prior PSMA PET scan showing at least one active cancer site.
Hear when a new Patients With Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.